down arrow

Titan Pharmaceuticals, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US8883147055
USD
3.34
0.21 (6.71%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

3.333.49

52 Week

2.8139.00
Valuation
Technical
Day's Volume

CASH

10.77 k

Shareholding (Mar 2025)

FII

0.00%

Held by 4 FIIs

DII

98.68%

Held by 1 DIIs

Promoter

0.00%

How big is Titan Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Titan Pharmaceuticals, Inc. has a market capitalization of 4.02 million, with net sales of 0.00 million and a net profit of -4.20 million for the latest four quarters ending in March 2025. As of December 2024, shareholder's funds were 2.44 million and total assets were 2.92 million.

Market Cap: As of Jun 18, Titan Pharmaceuticals, Inc. has a market capitalization of 4.02 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters ending in March 2025, Titan Pharmaceuticals reported net sales of 0.00 million and a net profit of -4.20 million.<BR><BR>Balance Sheet Snapshot: As of December 2024, the company's shareholder's funds amounted to 2.44 million, while total assets were reported at 2.92 million.

Read More

What does Titan Pharmaceuticals, Inc. do?

22-Jun-2025

Titan Pharmaceuticals, Inc. is a micro-cap specialty pharmaceutical company focused on developing therapeutics for medical disorders. As of March 2025, it has a market cap of $4.02 million and reported a net profit loss of $1 million.

Overview: <BR>Titan Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in developing therapeutics for medical disorders within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -1 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 4.02 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.04 <BR>Return on Equity: -224.24% <BR>Price to Book: 2.14<BR><BR>Contact Details: <BR>Address: 400 Oyster Point Blvd Ste 505, SOUTH SAN FRANCISCO CA: 94080-1958 <BR>Tel: ['1 650 2444990', '1 650 9892215'] <BR>Fax: 1 650 2444956 <BR>Website: https://www.titanpharm.com/

Read More

Who are in the management team of Titan Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, Titan Pharmaceuticals, Inc. is led by Dr. Marc Rubin as Executive Chairman and CEO, and Dr. Katherine DeVarney as President and COO, with several independent directors on the board.

As of March 2022, the management team of Titan Pharmaceuticals, Inc. includes Dr. Marc Rubin, who serves as the Executive Chairman of the Board and Chief Executive Officer. Dr. Katherine DeVarney holds the positions of President, Chief Operating Officer, Chief Scientific Officer, and Director. The board also includes several independent directors: Mr. Joseph Akers, Dr. M. David MacFarlane, Mr. James McNab, and Mr. Scott Smith. <BR><BR>In summary, as of March 2022, Titan Pharmaceuticals, Inc. is led by Dr. Marc Rubin and Dr. Katherine DeVarney, with a board comprising several independent directors.

Read More

Is Titan Pharmaceuticals, Inc. overvalued or undervalued?

25-Jun-2025

As of August 11, 2022, Titan Pharmaceuticals, Inc. is considered overvalued with a negative financial outlook, reflected in its high Price to Book Value of 2.26, a ROE of -224.24%, and concerning EV ratios, despite a year-to-date stock return of 36.50%.

As of 11 August 2022, Titan Pharmaceuticals, Inc. has moved from a grade of risky to does not qualify, indicating a significant deterioration in its valuation outlook. The company is currently deemed overvalued given its negative financial metrics, including a Price to Book Value of 2.26 and an alarming ROE of -224.24%. Additionally, the EV to EBIT and EV to EBITDA ratios are both at -0.57, reflecting a concerning financial position.<BR><BR>In comparison with its peers, Titan Pharmaceuticals shows a stark contrast, with Inhibikase Therapeutics, Inc. and Tenax Therapeutics, Inc. also not qualifying but exhibiting less severe metrics. The negative capital employed and the absence of a P/E ratio further highlight the company's struggles. Despite a recent stock return of 36.50% year-to-date, this does not compensate for the long-term underperformance against the S&P 500, which raises further concerns about the sustainability of its current valuation.

Read More

Is Titan Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of September 3, 2025, Titan Pharmaceuticals shows a mildly bullish trend based on daily moving averages and monthly MACD, but mixed signals from weekly indicators and significant historical underperformance compared to the S&P 500 suggest caution.

As of 3 September 2025, the technical trend for Titan Pharmaceuticals, Inc. has changed from sideways to mildly bullish. The daily moving averages indicate a mildly bullish stance, while the monthly MACD is also mildly bullish, suggesting some positive momentum. However, the weekly MACD and KST are mildly bearish, which introduces some mixed signals. The Bollinger Bands and Dow Theory show bearish tendencies on the weekly and monthly timeframes, indicating potential resistance.<BR><BR>In terms of performance, Titan Pharmaceuticals has underperformed compared to the S&P 500 over the past week, month, year, and longer periods, with a significant decline of 96.67% over the last five and ten years, while the S&P 500 has gained 96.61% and 231.64%, respectively. Overall, the current technical stance is mildly bullish, but caution is warranted due to the mixed indicators and significant historical underperformance.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 5 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.01

stock-summary
Return on Equity

-100.61%

stock-summary
Price to Book

1.95

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-1 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-20.48%
0%
-20.48%
6 Months
-29.98%
0%
-29.98%
1 Year
-15.76%
0%
-15.76%
2 Years
-51.1%
0%
-51.1%
3 Years
-82.23%
0%
-82.23%
4 Years
160.94%
0%
160.94%
5 Years
-8.24%
0%
-8.24%

Titan Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Titan Pharmaceuticals, Inc. technically bullish or bearish?

As of 3 September 2025, the technical trend for Titan Pharmaceuticals, Inc. has changed from sideways to mildly bullish. The daily moving averages indicate a mildly bullish stance, while the monthly MACD is also mildly bullish, suggesting some positive momentum. However, the weekly MACD and KST are mildly bearish, which introduces some mixed signals. The Bollinger Bands and Dow Theory show bearish tendencies on the weekly and monthly timeframes, indicating potential resistance. In terms of performance, Titan Pharmaceuticals has underperformed compared to the S&P 500 over the past week, month, year, and longer periods, with a significant decline of 96.67% over the last five and ten years, while the S&P 500 has gained 96.61% and 231.64%, respectively. Overall, the current technical stance is mildly bullish, but caution is warranted due to the mixed indicators and significant historical underperformance....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
13.03%
EBIT to Interest (avg)
-11.88
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.04
Sales to Capital Employed (avg)
-0.13
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
7.78%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.26
EV to EBIT
-0.57
EV to EBITDA
-0.57
EV to Capital Employed
-2.31
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-224.24%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 3 Schemes (1.32%)

Foreign Institutions

Held by 4 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs -100.00% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 66.67% vs -31.25% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.70",
          "val2": "-2.10",
          "chgp": "66.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.70",
          "val2": "-2.10",
          "chgp": "66.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs -66.67% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 16.07% vs 45.10% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.20",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.60",
          "val2": "-7.20",
          "chgp": "36.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.70",
          "val2": "-5.60",
          "chgp": "16.07%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-39,548.90%",
          "chgp": "3,954.89%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-0.70
-2.10
66.67%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-0.70
-2.10
66.67%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs -100.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 66.67% vs -31.25% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.20
-100.00%
Operating Profit (PBDIT) excl Other Income
-4.60
-7.20
36.11%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-4.70
-5.60
16.07%
Operating Profit Margin (Excl OI)
0.00%
-39,548.90%
3,954.89%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs -66.67% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 16.07% vs 45.10% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Titan Pharmaceuticals, Inc. stock-summary
stock-summary
Titan Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company's segment is engaged in the development of pharmaceutical products. The Company's product development programs utilize its long-term drug delivery platform, ProNeura. The Company's drug candidate, Probuphine, is being developed for the long-term maintenance treatment of opioid dependence. Titan's ProNeura continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The Company focuses on developing two product development programs, the first one with a ropinirole implant for the treatment of Parkinson's disease (PD) and the second one with a Triiodothyronine (T3) implant for the treatment of hypothyroidism.
Company Coordinates stock-summary
Company Details
400 Oyster Point Blvd Ste 505 , SOUTH SAN FRANCISCO CA : 94080-1958
stock-summary
Tel: 1 650 24449901 650 9892215
stock-summary
https://www.titanpharm.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."